ID | 50645 |
フルテキストURL | |
著者 |
Shien, Kazuhiko
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
ORCID
Kaken ID
publons
researchmap
Toyooka, Shinichi
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
ORCID
Kaken ID
publons
researchmap
Soh, Junichi
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
ORCID
Kaken ID
researchmap
Furukawa, Masashi
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
Maki, Yuho
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
Muraoka, Takayuki
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
Tanaka, Norimitsu
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
Ueno, Tsuyoshi
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
Asano, Hiroaki
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
Kaken ID
Tsukuda, Kazunori
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
ORCID
Kaken ID
publons
researchmap
Yamane, Masaomi
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
Kaken ID
researchmap
Oto, Takahiro
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
Kaken ID
publons
Kiura, Katsuyuki
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Resp Med
ORCID
Kaken ID
publons
researchmap
Miyoshi, Shinichiro
Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Canc & Thorac Surg
Kaken ID
publons
researchmap
|
抄録 | The expression of several cancer stem cell (CSC)-related markers has been confirmed in non-small cell lung cancer (NSCLC). The aim of this study was to clarify the clinical role of CSC-related markers in patients with NSCLC undergoing induction chemoradiotherapy (CRT). Fifty patients with clinically diagnosed N2 or N3 NSCLC who underwent induction CRT with docetaxel and cisplatin concurrently with thoracic radiation followed by surgery were examined in this study. The expressions of CSC related markers (CD133, ALDH1, ABCG2, and Bmi-1) were examined using immunohistochemical staining in surgically resected specimens. Among the 50 patients, 20 patients had no residual tumor cells in the resected specimen when examined pathologically; CSC-related marker expressions and their correlation to survival were evaluated in the other 30 patients. After a median follow-up period of 72 months, the 5-year overall survival rate of the patients with CD133-positive or ALDH1-positive specimens was significantly worse than that of the patients with both CD133-negative and ALDH1-negative expressions (449% vs. 90.0%, respectively; P=0.042). In a multivariate analysis. CD133 and ALDH1 negativity (P=0.047) and cN2-3 single station metastasis (P=0.03) were significant independent prognostic factors for prolonged survival. The expressions of CSC-related markers after CRT were significantly correlated with a poor prognosis in patients with NSCLC. The development of therapeutic strategies including adjuvant therapy that take CSC-related marker positivity into consideration is likely to be a key factor in further improvements of the prognosis of patients undergoing trimodality therapy.
|
キーワード | NSCLC
Cancer stem cell
CD133
ALDH1
Chemoradiotherapy
Induction therapy
|
発行日 | 2012-07
|
出版物タイトル |
Lung Cancer
|
巻 | 77巻
|
号 | 1号
|
出版者 | Elsevier Ireland Ltd.
|
開始ページ | 162
|
終了ページ | 167
|
ISSN | 0169-5002
|
NCID | AA10785743
|
資料タイプ |
学術雑誌論文
|
オフィシャル URL | http://dx.doi.org/10.1016/j.lungcan.2012.02.006
|
関連URL | http://ousar.lib.okayama-u.ac.jp/metadata/50697
|
言語 |
英語
|
著作権者 | (C) 2012 Elsevier Ireland Ltd. All rights reserved.
|
論文のバージョン | author
|
査読 |
有り
|
DOI | |
Web of Science KeyUT |